13 nominees · 4 ballot items.
Approve increase in authorized common shares; approve issuance of up to 16,000,000 shares in a PIPE at $3.25/share for Nasdaq 20% rule; approve issuance to Anchor Investor that may effect Nasdaq change of control; approve adjournment if needed to solicit additional votes.
Amend the certificate of incorporation to increase authorized common stock from 12,000,000 to 40,000,000 shares to enable closing of a Private Placement and provide flexibility for future corporate needs.
Proposal 1 requests shareholder approval to amend the Company’s Amended and Restated Certificate of Incorporation to increase authorized common stock from 12 million to 40 million shares. Management seeks this approval primarily to enable the closing of a Private Investment in Public Equity (PIPE) that requires additional authorized shares, and secondarily to provide flexibility for future equity issuances, including compensation, financing, and strategic transactions. The amendment is a prerequisite for the Private Placement described in the proxy, where the Company would issue up to 16 million shares at $3.25 per share; without this approval the Private Placement and related Credit Agreement Amendment (including a five-year interest rate reduction) cannot close. The board unanimously recommends approval, citing the need to strengthen the balance sheet, secure interest savings under the amended credit agreement, and provide operational liquidity. The proposal will dilute existing shareholders and could make hostile takeovers more difficult — risks the board acknowledges; directors, executive officers, and Investors also have conflicts of interest given voting agreements and potential personal benefits tied to the transaction. Approval has a simple majority of votes cast threshold; abstentions do not affect the outcome. The board did not obtain a fairness opinion, but relied on its advisors and determined the transaction is in the company’s best interests in light of liquidity needs and potential creditor concessions. The amendment’s effective timing is at the board’s discretion but must precede closing. If approved, newly authorized shares will be identical to existing common stock and there are no preemptive rights for existing holders.
Approve under Nasdaq Listing Rule 5635(d) issuance of up to 16,000,000 shares at $3.25 per share in the PIPE Purchase Agreement, which equals or exceeds 20% of outstanding shares at a price below Nasdaq's Minimum Price.
Proposal 2 asks shareholders to approve, under Nasdaq Rule 5635(d), the issuance of up to 16,000,000 shares at $3.25 per share in a private placement, which exceeds Nasdaq’s 20% threshold and is at a price below the Minimum Price, thus requiring shareholder approval. Management argues approval is necessary to consummate the Private Placement that would provide approximately $50 million of gross proceeds to improve liquidity and enable beneficial amendments to the Credit Agreement, including a material interest rate reduction. The issuance will substantially dilute existing shareholders’ ownership and could depress the public trading price once registration and resale occur. The board unanimously recommends approval, noting that without it the Private Placement and related creditor concessions (including interest savings) cannot proceed. Conflicts exist because certain directors and investors have voting agreements to support the proposals and will materially benefit from the transaction; supporting holders own ~42% pre-closing. The approval requires a majority of outstanding shares represented and voting; management did not secure a fairness opinion but engaged financial advisors in evaluating the transaction.
Approve under Nasdaq Listing Rule 5635(b) issuance of shares to the Anchor Investor that would result in a change of control because the Anchor Investor would own a majority post-issuance (approx. 52%).
Proposal 3 requests shareholder approval under Nasdaq Rule 5635(b) for the issuance of shares to the Anchor Investor that would result in the Anchor Investor and affiliates acquiring approximately 52% of outstanding shares, a change of control under Nasdaq interpretations. Management argues the approval is required to close the Private Placement which provides ~$50 million in proceeds and unlocks benefits under the Credit Agreement Amendment, including significant interest savings; absent approval the financing and lender concessions will not occur. The issuance would substantially dilute existing shareholders and shift control to the Anchor Investor, who will have board representation and is expected to become Chair; this raises governance and conflict-of-interest concerns given voting agreements and supporting holders’ positions. The board recommends approval, asserting the financing is necessary for liquidity and to implement strategic changes, while acknowledging potential negative impacts to minority holders. The approval requires a majority of outstanding shares represented and voting; management did not secure a fairness opinion but used advisors in evaluating alternatives.
Authorize the chair to adjourn the Special Meeting to solicit additional proxies, allow supplemental disclosures, or allow more time to consider other business if there are insufficient votes or other reasons.
Proposal 4 requests approval to adjourn the Special Meeting if necessary to solicit additional proxies, finalize and disseminate supplemental disclosures, or consider other business; management recommends approval to ensure the Company can secure required approvals for the Private Placement and related amendments. The adjournment power is standard in contested or conditional transactions and would allow the Company to meet vote thresholds or regulatory disclosure requirements. While beneficial to the Company’s ability to obtain approvals, adjournment authority can perpetuate uncertainty for shareholders and be used tactically to extend solicitation. The Board recommends a vote FOR to preserve flexibility to close the financing or comply with law and to allow more time if needed.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Solas Capital Management, LLC | 7.58% | 1,684,486 | $14M |
| 2 | GAMCO INVESTORS, INC. ET AL | 2.63% | 585,376 | $5M |
| 3 | CANNELL CAPITAL LLCActivist | 1.95% | 433,281 | $4M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1.13% | 252,159 | $2M |
| 5 | TRUIST FINANCIAL CORP | 0.99% | 219,966 | $2M |
| 6 | GABELLI FUNDS LLC | 0.99% | 219,199 | $2M |
| 7 | MILLENNIUM MANAGEMENT LLC | 0.46% | 102,248 | $880K |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 0.39% | 86,666 | $747K |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.28% | 61,623 | $531K |
| 10 | Private Advisor Group, LLC | 0.22% | 50,000 | $431K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.